Q32 Bio Inc. (QTTB)
NASDAQ: QTTB
· Real-Time Price · USD
1.64
0.08 (5.13%)
At close: May 02, 2025, 3:59 PM
1.64
0.31%
After-hours: May 02, 2025, 04:08 PM EDT
5.13% (1D)
| Bid | 1.63 |
| Market Cap | 19.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.73M |
| EPS (ttm) | -6.58 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.46 |
| Analyst | Hold |
| Ask | 1.73 |
| Volume | 169,461 |
| Avg. Volume (20D) | 221,525 |
| Open | 1.57 |
| Previous Close | 1.56 |
| Day's Range | 1.55 - 1.70 |
| 52-Week Range | 1.38 - 53.79 |
| Beta | -0.02 |
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other comp...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2018
Employees 42
Stock Exchange NASDAQ
Ticker Symbol QTTB
Website https://www.q32bio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for QTTB stock is "Hold." The 12-month stock price forecast is $12, which is an increase of 633.94% from the latest price.
Stock Forecasts2 months ago
-9.43%
Q32 Bio shares are trading lower after Piper Sandl...
Unlock content with
Pro Subscription
4 months ago
-28.57%
Q32 Bio shares are trading lower after Guggenheim downgraded the stock from Buy to Neutral.
